Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect <a target=_blank ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on NVAX stock, giving a Buy rating on November 13.Don't Miss our ...

On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...

Shares of Novavax (NVAX), a pharmaceutical company, declined over 6% following the release of its third-quarter results. Though the company reported a lower-than-expected loss and surpassed ...

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $7.76 which represents a decrease of $-0.70 or -8.27% from the prior close of $8.46. The stock opened at $8.44 and touched a low ...

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell?

In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $7.89 per share. By comparison ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...